Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) ...Middle East

SHANGHAI, Nov. 5, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, recently announced that the Center for Drug Evaluation...

Read More Details
Finally We wish PressBee provided you with enough information of ( Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) )

Also on site :

• Duke of Edinburgh makes flying visit to Wolverhampton school
• Terror-free Türkiye: Öcalan affirms terrorist group PKK ceased
• Princess Kate Moment That Turned William's Head Goes Viral